Gerald L. Klein

Gerald L. Klein, MD is a Clinical Immunologist. He is an expert in Medical Affairs and Clinical Development and has published numerous scientific papers. He was a professor of Medicine and Pediatrics (Division of Basic and Applied Immunology) at University California, Irvine.

Dr. Klein currently serves as the CMO of Claradele, an early-stage oncology company. He was a founder and CEO of Entera Health Inc., a GI biotherapeutics company. There, he created and managed both the clinical development and medical affairs programs. He was the Chief Medical Officer of Talecris/Grifols, and he was also its VP of Medical and Clinical Affairs. Dr. Klein has also been CMO/VP Medical and Clinical Affairs at several specialty biopharmaceutical companies including: Dey/MerckKgAa, Clingenix, Specialty Labs, Pathway Diagnosis: Oxygen Biotherapeutic/Tanex.

Dr. Klein began his career in industry by founding a CRO, San Diego Clinical Research Association, (SDCRA) where he served as CEO and CMO. SDCRA was acquired by Quintiles,(IQVIA) where Dr. Klein, was an SVP and worked in both Global Medical Affairs and Drug Development. Additionally, Dr. Klein has been on the Board of Directors of Nano Corp, Oxygen Biotherapeutics, and Plakous Therapeutics. Dr. Klein has served as an interim and part time CMO for multiple biotherapeutic companies. He is an associate editor and editorial board member of several publications as well as having an extensive list of peer review publications.